conatumumab
mapatumumab
guselkumab
monoclonal
-xizu-
carlumab
cibisatamab
lucatumumab
inotuzumab ozogamicin
sibrotuzumab
polyantigenic
heterophile
-i-
patritumab
oleclumab
immunoantigen
antigenomic
multiantigenic
drozitumab
alacizumab
oportuzumab monatox
panitumumab
idiospecific
lenzilumab
tabalumab
dalotuzumab
ABO antibodies
-lim-
siltuximab
perakizumab
robatumumab
pancytokeratin
polyclonal
-a-
hyperimmunoglobulin
dorlixizumab
bispecific
immunospecific
nofetumomab
toralizumab
teplizumab
antisubstance
immunoadsorbent
-toxa-
durvalumab
pritumumab
antihuman
agonistic monoclonal antibody
lexatumumab
immunoglobulin G